A phase 2 study of HKI-272 [neratinib] in subjects with advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2018
At a glance
- Drugs Neratinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 May 2012 Company (Puma Biotechnology) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.